Literature DB >> 15670878

The epidemiological contribution to the preparation of field trials for HIV and STI vaccines: objectives and methods of feasibility studies.

Barbara Suligoi1, Theresa M Wagner, Massimo Ciccozzi, Giovanni Rezza.   

Abstract

Feasibility studies are an important component of preparations for efficacy field trials of vaccine candidates, but represent a neglected area in clinical trial literature. These studies are designed to identify cohorts of higher-risk individuals with sufficiently high incidence to support a vaccine trial; to determine the readiness of these individuals to participate in a trial; to develop cost-effective recruitment and retention strategies, educational methods that ensure ethical informed consent, and instruments that accurately assess risk behaviours; to measure incidence rates over time and the effect of risk reduction interventions on incidence; to contribute estimates of incidence and loss to follow-up rates to sample size calculations; to assess the level of acceptability of a future efficacious vaccine in the target population and, in the case of several viruses, to identify circulating subtypes. Feasibility study methods have been largely developed in the context of HIV, but may also be used in the preparation of preventive intervention trials for other STI.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15670878     DOI: 10.1016/j.vaccine.2004.10.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  How informed is consent in vulnerable populations? Experience using a continuous consent process during the MDP301 vaginal microbicide trial in Mwanza, Tanzania.

Authors:  Andrew Vallely; Shelley Lees; Charles Shagi; Stella Kasindi; Selephina Soteli; Natujwa Kavit; Lisa Vallely; Sheena McCormack; Robert Pool; Richard J Hayes
Journal:  BMC Med Ethics       Date:  2010-06-13       Impact factor: 2.652

2.  Assessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study.

Authors:  Bethany White; Annie Madden; Maria Prins; Margaret Hellard; Handan Wand; Gregory J Dore; Kimberly Page; Lisa Maher
Journal:  Vaccine       Date:  2014-08-12       Impact factor: 3.641

3.  Engaging community businesses in human immunodeficiency virus prevention: a feasibility study.

Authors:  Liza S Rovniak; Melbourne F Hovell; C Richard Hofstetter; Elaine J Blumberg; Carol L Sipan; Marcia F Batista; Ana P Martinez-Donate; Mary M Mulvihill; Guadalupe X Ayala
Journal:  Am J Health Promot       Date:  2010 May-Jun

4.  Are women who work in bars, guesthouses and similar facilities a suitable study population for vaginal microbicide trials in Africa?

Authors:  Andrew Vallely; Ian R Hambleton; Stella Kasindi; Louise Knight; Suzanna C Francis; Tobias Chirwa; Dean Everett; Charles Shagi; Claire Cook; Celia Barberousse; Deborah Watson-Jones; John Changalucha; David Ross; Richard J Hayes
Journal:  PLoS One       Date:  2010-05-14       Impact factor: 3.240

5.  High prevalence of HIV infection among rural tea plantation residents in Kericho, Kenya.

Authors:  G Foglia; W B Sateren; P O Renzullo; C T Bautista; L Langat; M K Wasunna; D E Singer; P T Scott; M L Robb; D L Birx
Journal:  Epidemiol Infect       Date:  2007-06-29       Impact factor: 2.451

6.  Increased hepatitis C virus vaccine clinical trial literacy following a brief intervention among people who inject drugs.

Authors:  Bethany White; Annie Madden; Margaret Hellard; Thomas Kerr; Maria Prins; Kimberly Page; Gregory J Dore; Lisa Maher
Journal:  Drug Alcohol Rev       Date:  2012-11-01

7.  Risk Factor Detection as a Metric of STARHS Performance for HIV Incidence Surveillance Among Female Sex Workers in Kigali, Rwanda.

Authors:  Sarah L Braunstein; Janneke H van de Wijgert; Joseph Vyankandondera; Evelyne Kestelyn; Justin Ntirushwa; Denis Nash
Journal:  Open AIDS J       Date:  2012-09-07

8.  Microbicides development programme: engaging the community in the standard of care debate in a vaginal microbicide trial in Mwanza, Tanzania.

Authors:  Andrew Vallely; Charles Shagi; Shelley Lees; Katherine Shapiro; Joseph Masanja; Lawi Nikolau; Johari Kazimoto; Selephina Soteli; Claire Moffat; John Changalucha; Sheena McCormack; Richard J Hayes
Journal:  BMC Med Ethics       Date:  2009-10-09       Impact factor: 2.652

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.